CC
CRSP icon

Centiva Capital’s CRISPR Therapeutics CRSP Stock Holding History

Centiva Capital’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,200
Closed -$273K – 1751
2025
Q4 		$273K Sell
5,200
-20,000
-79% -$1.2M ﹤0.01% 883
2025
Q3 		$1.63M Buy
+25,200
New +$1.45M 0.02% 416

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Centiva Capital's CRSP Position: Q4 2021 in Review

Centiva Capital sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 1,987 shares — an estimated $222K sold.

Centiva Capital first reported a position in CRSP in Q3 2021 and held it in 1 quarter. The position peaked at $222K in Q3 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Centiva Capital reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Centiva Capital sold 1,987 CRISPR Therapeutics shares in Q4 2021, an estimated $222K.
  • Centiva Capital first reported a position in CRISPR Therapeutics in Q3 2021 and held it in 1 quarter.
  • Centiva Capital's CRISPR Therapeutics position peaked at $222K in Q3 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Centiva Capital's 13F filing for Q4 2021, filed 14 Feb 2022.